Mechelen, March 14th 2025 – Nipro PharmaPackaging and SHL Medical are pleased to announce the successful compatibility testing of SHL Medical’s Molly® 1.0 mL autoinjector and Nipro’s 1 mL long D2F™ pre-fillable glass syringes, as well as SHL Medical’s Molly® 2.25 mL autoinjector and Nipro’s 2.25 mL long D2F™ pre-fillable glass syringes.
The compatibility between the Molly® autoinjectors and D2F™ pre-fillable glass syringes was confirmed by successfully passing the following tests:
Molly Feasibility Study:
- Cap removal force
- Activation force
- Injection time
- Needle extension
- Dose accuracy
Syringe Characterization:
- Dimensional measurement
- Needle shield removal force
- Dose-volume
- Break loose
- Glide force
Lucy Lee, Associate Director, Product Management SHL Medical: "At SHL Medical, we prioritize strong partnerships with industry collaborators, such as Nipro. Through joint compatibility and feasibility assessments, we play an active role in mitigating risks associated with combination product development while accelerating time-to-market for our customers."
Charlotte Ostrowski-Leconte, Product Portfolio Manager NPI Pre-fillable Syringes, said: "We are happy to confirm the compatibility between the Molly devices and our D2F syringes. It confirms that our syringes meet the high standards required for use with SHL Medical’s advanced drug delivery devices, ensuring reliable and efficient performance for end-users."
For more information about Molly® devices, visit:
- https://www.shl-medical.com/products/autoinjectors/molly
- https://www.shl-medical.com/products/autoinjectors/molly-225
For more information about Nipro D2F™ pre-fillable glass syringe, visit:
Contact SHL Medical
Carl Gillblad - Head of Communications & Marketing Operations | +41 41 368 00 00 |
[email protected]
Contact Nipro
Annick Somers - Chief Marketing Officer | Marketing & PR – General | +32 15 26 35 54 |
[email protected]
About SHL Medical
As a world-leading solutions provider of advanced self-injection systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by its company purpose – Enabling Patients’ Independence – SHL Medical offers patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. It also offers final assembly, labeling, and packaging solutions for its drug delivery systems.
In response to the rising trend in home therapy, SHL Medical has increased its developmental work in the digital healthcare sector to help improve the drug delivery ecosystem.
Located across Switzerland, Taiwan, Sweden, and the US, SHL Medical’s global team of experts collaborate seamlessly as one team in utilizing its comprehensive in-house manufacturing capabilities. Its solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into its designs and processes to contribute to a cleaner earth.
About Nipro
Nipro PharmaPackaging specializes in developing and manufacturing advanced pharma packaging products and complete packaging solutions for early development drugs or enhancing packaging solutions for existing drugs. Nipro strives to be the preferred and trusted partner of pharmaceutical companies around the globe in safely delivering parenteral medicines to patients.
Nipro PharmaPackaging is part of Nipro Corporation Japan, established in 1954. As a leading global healthcare company with over 38,000+ employees worldwide, Nipro serves the Pharmaceutical, Medical Device, and Pharmaceutical Packaging industries. For more information, visit: www.nipro-group.com
